Upadacitinib hemihydrate

2050057-56-0

CAS-Nr.: 2050057-56-0

Englisch Name:: Upadacitinib hemihydrate

Synonyma:: Upadacitinib hemihydrate;ABT494 hemihydrate;ABT 494 hemihydrate;ABT-494 hemihydrate;Upadacitinib Hydrate;Cinchonanium, 1-[13,5-bis(trifluoromethyllphenyllmethyl]-9-hydroxy-1'- [[3-(trifluoromethyl)phenyllmethyl},bromide(1:2), (8a,9R)-";1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, hydrate (2:1), (3S,4R)-

CBNumber:: CB29872273

Summenformel:: C17H21F3N6O2

Molgewicht:: 398.39

MOL-Datei:: 2050057-56-0.mol

Request For Quotation

Eigenschaften Sicherheit Verwendungswort Produktionsfirma 72

Upadacitinib hemihydrate Eigenschaften

InChIKey: VJSRYIXHEWRBKD-NFGOAHBONA-N

SMILES: C([C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2C=NC3NC=CC=3N12)C.O |&1:1,13,r|

Sicherheit

Upadacitinib hemihydrate Chemische Eigenschaften,Einsatz,Produktion Methoden

Clinical Use

RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate. Each prolonged-release tablet (RINVOQ 15 mg prolonged-release tablets.) contains upadacitinib hemihydrate, equivalent to 15 mg of upadacitinib.

Upadacitinib hemihydrate Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Upadacitinib hemihydrate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 72)Lieferanten

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
TAIZHOU YUXIN BIOTECHNOLOGY CO,.LTD	+86-576-88902229;+86-0576-88902229 +8613968687450	yuxin@yuxchem.com	China	122	58
Taizhou Creating Bio-pharm co., ltd.	+8613586099526	post@creatingbiopharm.com	China	217	58
CONIER CHEM AND PHARMA LIMITED	+8618523575427	sales@conier.com	China	49391	58
Zhejiang J&C Biological Technology Co.,Limited	+1-2135480471 +1-2135480471	sales@sarms4muscle.com	China	10523	58
Heading （Nanjing）Pharmtechnologies Co., Ltd.	+86-25-58467899-832 +86-13382406280	liucheng@headingpharm.com	China	46	58
ShenZhen Trendseen Biological Technology Co.,Ltd.	13417589054	trendseenbio@gmail.com	China	11681	58
Jiangxi Chiyan Biopharmaceutical Technology Co.,Ltd.	+86-18616643091 +86-18616643091	info@rochipharma.com	China	246	58
Zibo Hangyu Biotechnology Development Co., Ltd	+86-0533-2185556 +8617865335152	Mandy@hangyubiotech.com	China	11013	58
Wuhan Jingkang en Biomedical Technology Co., Ltd	+8613720134139	orders@jknbiochem.com	China	4604	58
HANGZHOU KELAI BIOMEDICAL TECHNOLOGY Co., Ltd.	18957050573	752803249@qq.com	China	244	58

1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, hydrate (2:1), (3S,4R)-
Upadacitinib hemihydrate
Upadacitinib Hydrate
Cinchonanium, 1-[13,5-bis(trifluoromethyllphenyllmethyl]-9-hydroxy-1'- [[3-(trifluoromethyl)phenyllmethyl},bromide(1:2), (8a,9R)-"
ABT 494 hemihydrate
ABT494 hemihydrate
ABT-494 hemihydrate
2050057-56-0
API